RU2014112223A - Способ профилактики и/или лечения инсулинорезистентности - Google Patents
Способ профилактики и/или лечения инсулинорезистентности Download PDFInfo
- Publication number
- RU2014112223A RU2014112223A RU2014112223/15A RU2014112223A RU2014112223A RU 2014112223 A RU2014112223 A RU 2014112223A RU 2014112223/15 A RU2014112223/15 A RU 2014112223/15A RU 2014112223 A RU2014112223 A RU 2014112223A RU 2014112223 A RU2014112223 A RU 2014112223A
- Authority
- RU
- Russia
- Prior art keywords
- rel
- insulin resistance
- alcaligenes faecalis
- eubacterium hallii
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
Abstract
1. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.2. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения по п. 1, где осложнения, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.3. Фармацевтическая, пищевая или кормовая композиция, включающая Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.4. Фармацевтическая, пищевая или кормовая композиция по п. 3, отличающаяся тем, что указанные связанные с инсулинорезистентностью состояния выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.5. Способ профилактики и/или лечения инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью, у субъекта при наличии у него такой необходимости, отличающийся тем, что указанный способ включает стадию повышения уровня Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.6. Способ по п. 5, отличающийся тем, что уровень Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике повышают по методу, выбранному из группы, состоящей из введения эффективного количества Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. указанному субъекту и введения эффективного количества соединения, способного повысить уровень Eubactenum hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.7. Способ по п. 5 или 6, отличающийся тем, что указанные состояния, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного �
Claims (10)
1. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.
2. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения по п. 1, где осложнения, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
3. Фармацевтическая, пищевая или кормовая композиция, включающая Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.
4. Фармацевтическая, пищевая или кормовая композиция по п. 3, отличающаяся тем, что указанные связанные с инсулинорезистентностью состояния выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
5. Способ профилактики и/или лечения инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью, у субъекта при наличии у него такой необходимости, отличающийся тем, что указанный способ включает стадию повышения уровня Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.
6. Способ по п. 5, отличающийся тем, что уровень Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике повышают по методу, выбранному из группы, состоящей из введения эффективного количества Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. указанному субъекту и введения эффективного количества соединения, способного повысить уровень Eubactenum hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.
7. Способ по п. 5 или 6, отличающийся тем, что указанные состояния, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
8. Фармацевтическая, пищевая или кормовая композиция, включающая Alcaligenes faecalis et rel.
9. Композиция по п. 8, которая представляет собой напиток.
10. Фармацевтическая, пищевая или кормовая композиция, включающая Alcaligenes faecalis et rel., для применения в качестве лекарственного средства.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528931P | 2011-08-30 | 2011-08-30 | |
| NL2007319 | 2011-08-30 | ||
| US61/528,931 | 2011-08-30 | ||
| NL2007319 | 2011-08-30 | ||
| PCT/NL2012/050592 WO2013032328A1 (en) | 2011-08-30 | 2012-08-30 | Method for preventing and/or treating insulin resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014112223A true RU2014112223A (ru) | 2015-10-10 |
| RU2613322C2 RU2613322C2 (ru) | 2017-03-15 |
Family
ID=47756609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014112223A RU2613322C2 (ru) | 2011-08-30 | 2012-08-30 | Способ профилактики и/или лечения инсулинорезистентности |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9433650B2 (ru) |
| EP (1) | EP2753187B2 (ru) |
| JP (1) | JP6116568B2 (ru) |
| KR (1) | KR101982491B1 (ru) |
| CN (1) | CN104244733B (ru) |
| AU (1) | AU2012302364B2 (ru) |
| BR (1) | BR112014004890A8 (ru) |
| CA (1) | CA2851602C (ru) |
| DK (1) | DK2753187T4 (ru) |
| PL (1) | PL2753187T3 (ru) |
| RU (1) | RU2613322C2 (ru) |
| SG (1) | SG11201401811WA (ru) |
| WO (1) | WO2013032328A1 (ru) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| RU2737398C1 (ru) * | 2015-12-31 | 2020-11-30 | Калус Фармасьютикалс Б.В. | Способ культивирования и сохранения eubacterium hallii |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| US12343360B2 (en) | 2018-07-19 | 2025-07-01 | Pendulum Therapeutics Inc | Methods and compositions for microbial engraftment |
| US12544412B2 (en) | 2024-02-27 | 2026-02-10 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101982491B1 (ko) | 2011-08-30 | 2019-05-27 | 아카데미쉬 메디쉬 센트륨 | 인슐린 저항 예방 및/또는 치료 방법 |
| PT3628161T (pt) | 2012-11-23 | 2023-05-15 | Seres Therapeutics Inc | Composições bacterianas sinergísticas e métodos de produção e utilização das mesmas |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| JP6479685B2 (ja) | 2013-02-04 | 2019-03-06 | セレス セラピューティクス インコーポレイテッド | 病原性細菌生育の抑制のための組成物および方法 |
| WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| JP6637885B2 (ja) | 2013-07-21 | 2020-01-29 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム |
| ES3017865T3 (en) | 2013-11-25 | 2025-05-13 | Nestle Sa | Synergistic bacterial compositions and methods of production and use thereof |
| EP3082431A4 (en) | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| US11452746B2 (en) | 2015-01-09 | 2022-09-27 | Wageningen Universiteit | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
| CN106974939B (zh) * | 2016-01-15 | 2020-08-25 | 深圳华大生命科学研究院 | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 |
| CA3012466A1 (en) | 2016-02-02 | 2017-08-10 | Oncoimmune, Inc. | Use of cd24 proteins for treating leptin-deficient conditions |
| EP3419637B1 (en) | 2016-02-25 | 2021-01-27 | Caelus Pharmaceuticals B.V. | Compositions and methods for preventing and/or treating vitamin b12 deficiency |
| JP7012377B2 (ja) | 2016-04-11 | 2022-02-14 | ヴァーヘニンゲン ユニバーシテイト | 新規な細菌種 |
| BR112019004405A2 (pt) | 2016-09-07 | 2020-06-23 | Temple University - Of The Commonwealth System Of Higher Education | Compostos e seus usos para aumentar a sensibilidade à insulina, reduzir a resistência à insulina e/ou prevenir a resistência à insulina e para tratar um distúrbio de resistência à insulina e composição os compreendendo |
| ES3052742T3 (en) * | 2017-01-19 | 2026-01-13 | Bactaviva Ab | Autologous fecal sample for use in the treatment of microbial dysbiosis |
| JP2020530840A (ja) | 2017-08-14 | 2020-10-29 | セレス セラピューティクス インコーポレイテッド | 胆汁うっ滞性疾患を治療するための組成物及び方法 |
| RU2020117775A (ru) | 2017-10-30 | 2021-12-01 | Серес Терапеутикс, Инк. | Композиции и способы для лечения устойчивости к антибиотикам |
| EP3758721B1 (en) * | 2018-03-02 | 2022-05-18 | Academisch Medisch Centrum | Fecal matter for prevention or treatment of autoimmune diseases |
| WO2020056298A1 (en) | 2018-09-13 | 2020-03-19 | Assembly Biosciences, Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| MX2021012391A (es) | 2019-04-09 | 2022-01-18 | Dermbiont Inc | Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos. |
| NL2024569B1 (en) | 2019-12-24 | 2021-09-06 | Univ Wageningen | Bacterium comprising myo-inositol to propionate pathway |
| WO2021028585A1 (en) | 2019-08-14 | 2021-02-18 | Wageningen Universiteit | Bacterium comprising myo-inositol to propionate pathway |
| RU2734336C1 (ru) * | 2020-03-27 | 2020-10-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ ранней неинвазивной диагностики метаболических нарушений у детей и подростков |
| TW202206062A (zh) | 2020-04-24 | 2022-02-16 | 美國坦普大學 高等教育聯邦系統 | 治療非酒精性脂肪肝炎的方法 |
| EP4228665A1 (en) * | 2020-10-14 | 2023-08-23 | Dermbiont, Inc. | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with fungi and other pathogenic microbes |
| CN113604400B (zh) * | 2021-08-26 | 2023-06-02 | 王玉莹 | 具有预防或治疗糖尿病作用的新型乳杆菌yuyingw |
| NL2036594B1 (en) | 2023-12-20 | 2025-07-04 | Univ Wageningen | Bacterium comprising phytate-degradation pathway |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| CZ81997A3 (en) * | 1996-03-20 | 1997-10-15 | Immuno Ag | Pharmaceutical preparation for treating disorders connected with blood clotting, process of its preparation and use |
| US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
| US6227863B1 (en) | 1998-02-18 | 2001-05-08 | Donald Spector | Phonics training computer system for teaching spelling and reading |
| US6224863B1 (en) | 1998-10-30 | 2001-05-01 | University Of South Carolina | Antibiotic composition from alcaligenes species and method for making and using the same |
| EP1228769A1 (de) * | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiontisches Regenerativum |
| JP4307006B2 (ja) * | 2002-03-28 | 2009-08-05 | キリンフードテック株式会社 | 糖尿病予防剤 |
| CA2492805C (en) † | 2002-07-18 | 2015-05-12 | Agricultural Research Council | Megasphaera elsdenii strain and its uses |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| US8119377B2 (en) † | 2004-12-22 | 2012-02-21 | Michigan Biotechnology Institute | Recombinant microorganisms for increased production of organic acids |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| EP2102350A4 (en) | 2006-12-18 | 2012-08-08 | Univ St Louis | DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES |
| JP5350626B2 (ja) * | 2007-12-20 | 2013-11-27 | キリンフードテック株式会社 | 樹状細胞活性化用組成物 |
| US20110189149A1 (en) † | 2008-06-20 | 2011-08-04 | Remy Burcelin | New Uses of Lactic Acid Bacteria and Bifidobacteria |
| US9603876B2 (en) * | 2008-09-25 | 2017-03-28 | New York University | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment |
| US8337667B2 (en) * | 2009-01-23 | 2012-12-25 | Kadant, Inc. | Systems and methods for providing improved dewatering performance in a papermaking machine |
| US20120027737A1 (en) † | 2009-03-25 | 2012-02-02 | Chr-Hansen A/S | Use of probiotics to ameliorate diet-induced insulin resistance |
| US20120238468A1 (en) * | 2009-10-05 | 2012-09-20 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
| WO2011145516A1 (ja) | 2010-05-18 | 2011-11-24 | エイブル株式会社 | メタン生成の抑制方法 |
| WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| KR101982491B1 (ko) | 2011-08-30 | 2019-05-27 | 아카데미쉬 메디쉬 센트륨 | 인슐린 저항 예방 및/또는 치료 방법 |
| JP2019500035A (ja) † | 2015-12-31 | 2019-01-10 | カエルス ファーマシューティカルズ ビー．ヴィ． | ユーバクテリウム・ハリー（Ｅｕｂａｃｔｅｒｉｕｍ ｈａｌｌｉｉ）を培養し、保存する方法 |
-
2012
- 2012-08-30 KR KR1020147008451A patent/KR101982491B1/ko active Active
- 2012-08-30 PL PL12758652T patent/PL2753187T3/pl unknown
- 2012-08-30 SG SG11201401811WA patent/SG11201401811WA/en unknown
- 2012-08-30 CN CN201280053708.2A patent/CN104244733B/zh active Active
- 2012-08-30 WO PCT/NL2012/050592 patent/WO2013032328A1/en not_active Ceased
- 2012-08-30 AU AU2012302364A patent/AU2012302364B2/en active Active
- 2012-08-30 JP JP2014528318A patent/JP6116568B2/ja active Active
- 2012-08-30 BR BR112014004890A patent/BR112014004890A8/pt not_active Application Discontinuation
- 2012-08-30 CA CA2851602A patent/CA2851602C/en active Active
- 2012-08-30 US US14/241,851 patent/US9433650B2/en active Active
- 2012-08-30 DK DK12758652.7T patent/DK2753187T4/da active
- 2012-08-30 EP EP12758652.7A patent/EP2753187B2/en active Active
- 2012-08-30 RU RU2014112223A patent/RU2613322C2/ru active
-
2016
- 2016-07-11 US US15/207,335 patent/US9623055B2/en active Active
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590176B2 (en) | 2012-02-29 | 2023-02-28 | Johnson & Johnson Consumer Inc. | Compositions of microbiota and methods related thereto |
| US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US12048721B2 (en) | 2012-02-29 | 2024-07-30 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10729732B2 (en) | 2012-02-29 | 2020-08-04 | Ethicon Endo Surgery, Inc. | Compositions of microbiota and methods related thereto |
| US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| RU2737398C1 (ru) * | 2015-12-31 | 2020-11-30 | Калус Фармасьютикалс Б.В. | Способ культивирования и сохранения eubacterium hallii |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| US12233095B2 (en) | 2017-08-30 | 2025-02-25 | Pendulum Therapeutics Inc | Methods and compositions for treatment of microbiome associated disorders |
| US12343360B2 (en) | 2018-07-19 | 2025-07-01 | Pendulum Therapeutics Inc | Methods and compositions for microbial engraftment |
| US12544412B2 (en) | 2024-02-27 | 2026-02-10 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140294774A1 (en) | 2014-10-02 |
| BR112014004890A8 (pt) | 2018-02-06 |
| PL2753187T3 (pl) | 2019-05-31 |
| CA2851602A1 (en) | 2013-03-07 |
| US20160317589A1 (en) | 2016-11-03 |
| EP2753187B1 (en) | 2018-10-24 |
| CA2851602C (en) | 2020-07-14 |
| SG11201401811WA (en) | 2014-09-26 |
| WO2013032328A1 (en) | 2013-03-07 |
| KR20140128936A (ko) | 2014-11-06 |
| EP2753187B2 (en) | 2025-08-06 |
| JP6116568B2 (ja) | 2017-04-19 |
| AU2012302364A1 (en) | 2014-04-17 |
| US9623055B2 (en) | 2017-04-18 |
| JP2014527068A (ja) | 2014-10-09 |
| BR112014004890A2 (pt) | 2017-03-21 |
| DK2753187T3 (en) | 2019-01-28 |
| RU2613322C2 (ru) | 2017-03-15 |
| CN104244733A (zh) | 2014-12-24 |
| KR101982491B1 (ko) | 2019-05-27 |
| DK2753187T4 (da) | 2025-10-20 |
| AU2012302364B2 (en) | 2016-07-28 |
| US9433650B2 (en) | 2016-09-06 |
| CN104244733B (zh) | 2017-07-28 |
| EP2753187A1 (en) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014112223A (ru) | Способ профилактики и/или лечения инсулинорезистентности | |
| HK1211232A1 (en) | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists | |
| PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| WO2017009236A3 (en) | New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists | |
| IN2014KN02830A (ru) | ||
| PH12016500959B1 (en) | Use of nutritional compositions having a low protein amount | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| AR083920A1 (es) | Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21) | |
| AR081581A1 (es) | Un proceso para la preparacion de te | |
| WO2011092473A8 (en) | Novel compounds and their effects on feeding behaviour | |
| WO2016068453A8 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| WO2013028017A3 (ko) | 고분자량 실크 피브로인을 함유하는 혈당 및 콜레스테롤 강하용 조성물 및 그 제조방법 | |
| WO2016048005A3 (ko) | 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 | |
| EA201791173A1 (ru) | Композиция, содержащая пентозу и полифенольное соединение | |
| WO2012138146A3 (ko) | 돌콩의 열처리분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물 | |
| WO2012105816A3 (ko) | 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물 | |
| WO2013098842A3 (en) | Novel film coating composition | |
| EA201270238A1 (ru) | Пищевая композиция, содержащая гликоген | |
| WO2012154009A3 (ko) | 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 | |
| Милановић et al. | Market of agricultural and foodstuff products in Serbia before and after transition | |
| WO2011139010A1 (ko) | 피페로날을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간 또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 |